Lion Corporation (4912) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
12 Sep, 2026Executive summary
Net sales and profits increased year-over-year for the first nine months of 2025, with core operating income up 19.9% and profit attributable to owners rising 64.3%, driven by high value-added products, profit structure reforms, and overseas expansion, including a profitable Vietnam subsidiary.
Both domestic and overseas businesses contributed to growth, with Japan showing improved momentum and overseas adapting to environmental changes, though Northeast Asia faced declines.
Financial highlights
Net sales for the first three quarters reached ¥304,945 million, up 1.3% year-over-year; Q3 sales growth was 2.9%.
Core operating income was ¥22,320 million, up 19.9% year-over-year; EBITDA reached ¥35,500 million with an 11.7% margin.
Profit attributable to owners surged 64.3% to ¥20,813 million, aided by a gain on step acquisition and consolidation of a Vietnam subsidiary.
EPS climbed 64.8% to ¥75.25.
Outlook and guidance
Full-year 2025 forecast remains unchanged: net sales ¥420,000 million, core operating income ¥30,000 million, profit attributable to owners ¥25,000 million, and basic EPS ¥90.24.
Flexible expense investment in Q4 is planned to achieve annual goals, with continued focus on cost reduction, price pass-through, and high value-added products.
Dividend expected to increase by ¥3 to ¥30 per share, marking the 10th consecutive year of increases.
Latest events from Lion Corporation
- Prioritizing high-value oral care and local leadership to drive profitable growth in Asia.4912
Investor update - Profits and sales surged, driven by overseas growth and price increases.4912
Q2 2024 - Core operating income surged 47.8% on modest sales growth, led by overseas expansion.4912
Q3 2024 - Profits and sales increased, led by overseas and oral healthcare growth, with higher dividends planned.4912
Q4 2024 - Sales and profits increased year-over-year, driven by overseas growth and higher dividends.4912
Q1 2025 - Core operating income rose 32.3% as overseas expansion and margin gains continued.4912
Q2 2025 - 2025 profit and margin growth exceeded targets; 2026 aims for further gains and higher dividends.4912
Q4 2025 - Q1 sales and profit rose 5.3%, led by oral care and overseas gains despite cost headwinds.4912
Q1 2026 - Strong sales and profit growth led by Oral Healthcare and overseas gains, with higher dividend.4912
Q2 2026